Beyond epithelial damage: vascular and endothelial contributions to idiopathic pulmonary fibrosis
James May, Jane A. Mitchell, R. Gisli Jenkins
James May, Jane A. Mitchell, R. Gisli Jenkins
View: Text | PDF
Review

Beyond epithelial damage: vascular and endothelial contributions to idiopathic pulmonary fibrosis

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive scarring disease of the lung with poor survival. The incidence and mortality of IPF are rising, but treatment remains limited. Currently, two drugs can slow the scarring process but often at the expense of intolerable side effects, and without substantially changing overall survival. A better understanding of mechanisms underlying IPF is likely to lead to improved therapies. The current paradigm proposes that repetitive alveolar epithelial injury from noxious stimuli in a genetically primed individual is followed by abnormal wound healing, including aberrant activity of extracellular matrix–secreting cells, with resultant tissue fibrosis and parenchymal damage. However, this may underplay the importance of the vascular contribution to fibrogenesis. The lungs receive 100% of the cardiac output, and vascular abnormalities in IPF include (a) heterogeneous vessel formation throughout fibrotic lung, including the development of abnormal dilated vessels and anastomoses; (b) abnormal spatially distributed populations of endothelial cells (ECs); (c) dysregulation of endothelial protective pathways such as prostacyclin signaling; and (d) an increased frequency of common vascular and metabolic comorbidities. Here, we propose that vascular and EC abnormalities are both causal and consequential in the pathobiology of IPF and that fuller evaluation of dysregulated pathways may lead to effective therapies and a cure for this devastating disease.

Authors

James May, Jane A. Mitchell, R. Gisli Jenkins

×

Figure 2

ECs support healthy vasculature and undergo dramatic changes in IPF.

Options: View larger image (or click on image) Download as PowerPoint
ECs support healthy vasculature and undergo dramatic changes in IPF. (A)...
(A) Damaged epithelium releases active TGF-β and other profibrotic mediators. The original injury also disrupts the BM and the neighboring endothelial layer, which responds to the profibrotic signal. ECs subsequently secrete similar profibrotic mediators and lose the ability to synthesize protective hormones such as eNOS and prostacyclin. This process can stimulate VEGF production, which drives EC proliferation, and ECs distributed throughout the lung propagate fibrosis. Compared with healthy lungs, IPF lungs have a higher proportion of apoptotic ECs, fibroblasts, pericytes, and VSMCs. Cellular proliferation and newly generated vessels expand affected lung tissue. With progressive vascular pathology there is ultimately advanced tissue destruction, and eventually vascular regression develops in the fibroblastic foci. (B) In IPF, the EC participates in several cell-cell interactions and cell transitions. Damaged ECs produce factors that signal to other ECs and promote damage or drive the transition to other cell types: (i) EC-fibroblast: ECs transition into a fibroblast-type cell via EndMT to contribute to the pool of profibrotic cells. (ii) EC-myofibroblast: Damaged ECs also secrete TGF-β, PDGF, and Jag1 to enhance fibroblast-myofibroblast transition and ECM secretion. (iii) EC-EC: Abnormal ECs secrete VEGF, which promotes EC proliferation and abnormal vessel formation, thus contributing to the pool of ECs that can propagate this process. Compromised tight junctions leak coagulation factors, driving fibrosis. (iv) EC-VSMC: EC production of TGF-β and ET1 promotes VSMC proliferation, contributing to PH and a switch to a synthetic phenotype. (v) EC–epithelial cell: Downregulation of protective factors such as MMP-14 delays epithelial repair, allowing persistent epithelial-mesenchymal crosstalk. (vi) Pericyte-myofibroblast: Disrupted Wnt signaling associated with ECs drives pericytes to transition into a myofibroblast-type cell.